|Articles|May 26, 2023
Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart
Author(s)Chris Spivey
Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.
Advertisement
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
4
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
5
